Traws Pharma Inc
$ 1.53
6.99%
24 Feb - close price
- Market Cap 19,417,800 USD
- Current Price $ 1.53
- High / Low $ 1.58 / 1.38
- Stock P/E N/A
- Book Value 0.64
- EPS -1.82
- Next Earning Report 2026-03-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.92 %
- ROE -10.60 %
- 52 Week High 3.96
- 52 Week Low 0.97
About
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. The company is headquartered in Newtown, Pennsylvania.
Analyst Target Price
$8.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-14 | 2025-05-13 | 2025-03-31 | 2024-11-14 | 2024-08-15 | 2024-05-15 | 2024-03-14 | 2023-11-14 | 2023-08-10 | 2023-05-15 | 2023-03-16 |
| Reported EPS | -0.34 | -0.16 | 22.4413 | 26.6 | -8.81 | -4.8652 | -0.19 | -0.19 | -0.23 | -0.2 | -0.28 | -0.26 |
| Estimated EPS | -9.16 | -8.75 | -0.265 | -0.25 | -6.25 | -6.25 | -0.23 | -0.25 | -0.29 | -0.31 | -0.3 | -0.26 |
| Surprise | 8.82 | 8.59 | 22.7063 | 26.85 | -2.56 | 1.3848 | 0.04 | 0.06 | 0.06 | 0.11 | 0.02 | 0 |
| Surprise Percentage | 96.2882% | 98.1714% | 8568.4151% | 10740% | -40.96% | 22.1568% | 17.3913% | 24% | 20.6897% | 35.4839% | 6.6667% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-30 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.91 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TRAW
2026-02-19 22:25:51
Traws Pharma announced positive Phase 2 clinical data for its COVID-19 treatment, ratutrelvir, showing fewer side effects, quicker symptom resolution, and no viral rebounds compared to Paxlovid. Concurrently, their seasonal influenza prophylactic, tivoxavir marboxil (TXM), demonstrated potential for monthly use but faces a clinical hold by the FDA due to mutagenicity concerns. The market reacted negatively, with TRAW stock declining significantly despite the promising COVID-19 drug results.
2026-02-19 14:57:53
Traws Pharma (NASDAQ:TRAW) stock plummeted 27% after the FDA placed its influenza treatment candidate, tivoxavir marboxil, on clinical hold due to concerns with its mutagenicity data. The FDA plans to formally communicate its concerns by March 16, 2026, which marks a significant setback for the company's pipeline despite positive news regarding their COVID-19 treatment, ratutrelvir. The clinical hold does not affect studies outside the U.S.
2026-02-19 13:57:53
Traws Pharma has completed a Phase 2 analysis of ratutrelvir, showing fewer adverse events, no viral rebounds, and faster symptom resolution compared to PAXLOVID for mild-to-moderate COVID-19. Additionally, a preclinical tablet formulation of tivoxavir marboxil demonstrated potential for 28-day influenza protection, although its US IND is currently on clinical hold by the FDA due to mutagenicity data. The FDA is expected to provide specific concerns and mitigation steps by March 16, 2026.
2026-02-19 13:57:53
Traws Pharma reported positive Phase 2 data for its COVID-19 drug, ratutrelvir, showing better tolerability and faster symptom resolution than PAXLOVID, with no viral rebound. The company also made progress with tivoxavir marboxil for flu prophylaxis, though its U.S. program faces regulatory uncertainty due to an FDA clinical hold. Despite these developments, TipRanks' AI Analyst, Spark, rates TRAW as Neutral due to weak financial performance offsetting positive pipeline catalysts.
2026-02-19 12:57:53
Traws Pharma announced positive Phase 2 clinical results for ratutrelvir, an oral COVID-19 treatment, showing a differentiated profile from PAXLOVID® with fewer adverse events and no viral rebounds, especially for patients unable to take PAXLOVID®. The company also reported progress on tivoxavir marboxil for influenza prevention, with increased exposure suggesting 28-day protection, though its U.S. IND faces a clinical hold due to safety concerns. Traws Pharma aims to address critical health challenges with these antiviral therapies despite the regulatory setback for tivoxavir marboxil.
2026-02-18 00:28:10
Ayrton Capital LLC reduced its stake in Traws Pharma Inc. by selling 60,715 shares, valued at $1.13 each, on December 31, 2025. This transaction leaves Ayrton Capital with 342,935 shares of Traws Pharma, representing 4.29% of its portfolio in the company. Traws Pharma Inc., a clinical-stage biopharmaceutical company focused on respiratory viral diseases, exhibits financial metrics suggesting potential caution for value investors, including a low GF-Score and negative revenue growth, despite recent stock gains.
